PUBLISHER: IMARC | PRODUCT CODE: 1541099
PUBLISHER: IMARC | PRODUCT CODE: 1541099
The global viral inactivation market size reached US$ 635.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,390.8 Million by 2032, exhibiting a growth rate (CAGR) of 8.8% during 2024-2032.
Biotherapeutic products contain viruses or they can become contaminated during the production process. Viruses are infectious particles that invade cells wherein they proliferate and result in various diseases. As a result, viral inactivation is widely used to inhibit coat proteins and degrade nucleic acid within the virus. At present, different methods of viral inactivation are available across the globe according to the characteristics of the virus and the type of biotherapeutic product. For instance, germicidal (UVC) light exposure helps inactivate viruses in hospitals and other critical public and military environments.
Human blood is a source of medicinal products that assists in the prevention and treatment of life-threatening diseases. Rising concerns about the transmission of blood-borne viruses through plasma-derived medicinal products represent one of the significant factors influencing the need for viral inactivation around the world. Several procedures for viral inactivation are nowadays used to assure the safety of blood plasma-derived protein solutions. Moreover, governing agencies of numerous countries are introducing stringent regulatory standards at an early stage in the development of biotherapeutic products. These standards are escalating the demand for viral inactivation to ensure the quality, safety, and efficacy of these products, thereby reducing the risk of cross-contamination. Apart from this, improved viral inactivation technologies and products are being employed in the food and beverage (F&B) industry to help control the transmission of enteric viruses and assure the safety of products. This, in confluence with the development of new physical methods like supercritical fluids, gas plasma, and pulsed electric fields, is anticipated to increase the reliability, convenience, and suitability of viral inactivation, thereby driving the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global viral inactivation market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and end use.
Reagents and Kits
Systems
Services
Vaccines and Therapeutics
Stem Cell Products
Blood and Blood Products
Tissue and Tissue Products
Cellular and Gene Therapy
Pharmaceutical and Biotechnology Companies
CROs
Academic and Research Institutes
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories, Merck KGaA, Parker Hannifin Corp, Rad Source Technologies, Sartorius AG, SGS SA, Terumo Corporation, Texcell, Vironova AB and WuXi AppTec.